PARPi are a group of antineoplastic drugs that were developed for the treatment of patients diagnosed with mutations in the breast cancer type 1 susceptibility protein 1 and 2 (BRCA1/2) genes, i.e., for breast and ovarian cancer patients. This evidence concerns the gene BRCA1 and ovarian carcinoma.